Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/00, \ 30/o9/01, \ 11/o3/02, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12 \ \ o1/o1/o3, \ o1$ 

4 086	778 476	
Ve (th	e entity) give ASX the followi	ng information.
-	- All issues t complete the relevant sections (atto	ach sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued to be issued (if known) of maximum number which may be issued	or
3	Principal terms of the *securitie (eg, if options, exercise price are expiry date; if partly pa *securities, the amount outstanding and due dates for payment; if *convertib securities, the conversion pricand dates for conversion)	ad a

Name of entity

ABN

Actinogen Medical Limited

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes – the shares issued rank equally with existing listed fully paid ordinary shares.
	merese payment	
5	Issue price or consideration	\$0.02 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of unlisted 30 November 2018 options
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes.
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
<i>c</i> 1	mi 1, ,1	N. I.
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2016
6с	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	3,500,000 (Exception 4)	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 87,529,033 7.1A 62,019,355	
	7 milo difeements		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	9 May 2017	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	620,193,558	Fully paid ordinary shares (ACW)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
40,500,000	Unlisted options exercisable at 2 cents each on or before 30 November 2018.
4,950,000	Unlisted options exercisable at \$0.10 each on or before 5 February 2021 and subject to vesting conditions.
5,000,000	Unlisted options exercisable at \$0.10 each on or before 24 March 2025 and subject to vesting conditions.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable			

### Part 2 - Bonus issue or pro rata issue - Not Applicable

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the <sup>+</sup> securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
_0		
21	Amount of any underwriting fee	
21	or commission	
22	Names of any brokers to the issue	
22	runies of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee	
	payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
	If the issue is continuent on	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance	
20	form and prospectus or Product Disclosure Statement will be sent to persons entitled	
277	If the entity has issued options,	
27	and the terms entitle option	
	holders to participate on exercise, the date on which notices will be sent to option holders	
	-	
28	Date rights trading will begin (if applicable)	
3.0	Date wights trading will and /if	
29	Date rights trading will end (if applicable)	

<sup>+</sup> See chapter 19 for defined terms.

Appe	endix	3B			
New	issue	ann	ound	eme	nt

30		do *security holders sell ntitlements <i>in full</i> through er?	
31			
32	of thei	o *security holders dispose r entitlements (except by rough a broker)?	
33	<sup>+</sup> Despa	tch date	
		otation of securities	blying for quotation of securities
34	Type of (tick or	f securities ne)	
(a)	X	Securities described in Part	1
(b)			nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es that h	ave ticked box 34(a)	
Addit	ional se	curities forming a new	class of securities
Tick t docun		you are providing the informat	tion or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	1		v securities, a distribution schedule of the additional umber of holders in the categories

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

	100,001 and over		
37	A copy of any trust deed for t	the additional <sup>+</sup> securities	
Entities	s that have ticked box 34(b)		
38	Number of securities for which <sup>+</sup> quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)		

Quotation agreement

<sup>+</sup> See chapter 19 for defined terms.

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Peter Webse Company secretary

Date: 9 May 2017

Appendix 3B Page 8 o1/08/2012

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities – Not applicable

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exc	ceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	606,693,558	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	10,000,000 issued 26 April 2017 3,500,000 issued 9 May 2016	
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> </ul>		
<ul> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	-	
" <b>A</b> " 620,193,558		

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	93,029,033
Step 3: Calculate "C", the amount 7.1 that has already been used	t of placement capacity under rule
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	500,000 unlisted options 6 February 2017 5,000,000 unlisted options 24 March 2017
• Under an exception in rule 7.2	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	5,500,000
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1	
"A" x 0.15	93,029,033
Note: number must be same as shown in Step 2	
Subtract "C"	5,500,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	87,529,033
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	62,029,355
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"E"	-

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	62,029,355
Note: number must be same as shown in Step 2	
Subtract "E"	-
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	62,029,355
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.